Secondary Logo

Journal Logo

Review article

Prurigo nodularis – an update on an important disease

Tsianakas, Athanasios; Zeidler, Claudia; Riepe, Claudia; Ständer, Sonja

Author Information
Journal of the Egyptian Women’s Dermatologic Society: September 2016 - Volume 13 - Issue 3 - p 119-124
doi: 10.1097/01.EWX.0000481472.60356.9e
  • Free



Prurigo nodularis (PN) is a clinical pattern defined by multiple, typically symmetrically distributed papules and nodules that are often erosive and ulcerative. PN belongs to the spectrum of chronic pruritic diseases, and development of its itchy lesions is based on a vicious itch–scratch cycle. Etiologically, it could be shown that 50% of the patients with PN have a concomitant atopic disease 1. Moreover, there are various other dermatological potentially pruritic diseases such as bullous pemphigoid and lichen planus that can lead to PN. In addition, there is a variety of internal medical diseases that can be associated with PN (e.g. chronic kidney and liver diseases, tumors, diabetes mellitus, chronic iron deficiency, and many others), as well as neurological and psychiatric diseases 2. Therefore, PN can be a result of chronic pruritus of diverse origin, and thus a thorough medical examination should always be carried out to reveal any potential underlying disease.


An intensive literature research was performed on PN using different electronic medical databases such as Medline and DIMDI. The key words used were ‘prurigo nodularis’ and ‘prurigo nodularis’ in combination with ‘epidemiology’, ‘pathophysiology’, ‘treatment’, and ‘therapy’. In what follows, we would like to highlight the pathophysiology, the clinical picture, the connection to the underlying diseases, and the treatment options for PN.



There are only a few studies in the literature reporting the frequency of PN among dermatological diseases, mostly from Asia 3,4. In these publications, PN is reported as to be among the top 20 of the most common dermatological diseases, and its prevalence ranges from 1.82 to 3.8% 3,4. Most often, elderly patients are affected, but there are other reports even about affected children 5. Women seem to be more often affected than men (female : male=1.7 : 1), and the age of onset is about 60 years 2. There does not seem to exist a link of PN to genetic factors 6.


Historically, for a long time histamine was thought to be the major itch-inducing mediator of PN 7. However, high treatment-failure rates of the antihistaminic therapy have led to a deeper insight into the pathogenesis of PN. Histopathologically, increased numbers of eosinophilic granulocytes, T-cells, and mast cells can be found in the lesions of PN. Based on the infiltration with eosinophilic granulocytes, there are high amounts of eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil protein X in PN lesions 8. In addition, it could be detected that the T-cell-derived cytokine interleukin (IL)-31 is upregulated in PN lesions 9. This is also known from atopic dermatitis in which IL-31 serum levels even correlate with disease severity 9,10. Furthermore, IL-31 is known to induce inflammation and pruritus.

Most recently, there is a focus on changes of the neuroanatomy in PN lesions. Chronic mechanical irritation by scratching seems to lead to proliferation of keratinocytes, fibroblasts, mast cells, collagenous fibers, and dermal nerve fibers 8,11. Recently, an immunohistochemical study has been published, in which it has been shown that there is an increased expression of the nerve growth factor (NGF) in epidermal keratinocytes with PN 11. But there exist many other neuropeptides such as substance P, calcitonin gene-related peptide, and the receptor of NGF (TrkA p75NGF) that are increased in PN lesions as well 12,13. Increase of neuropeptides can lead to nerve growth, but also to inflammation and pruritus, which might be the link between the neurohistological findings and the clinical picture. The itch (reason for inflammation and pruritus)–scratch (causes mechanical irritation with the consequence of inflammation and pruritus) cycle keeps the disease permanently going.

Clinical appearance of prurigo nodularis

PN is typically characterized by symmetrically distributed erythematous papules, nodules, and plaques that are highly pruritic. Their number can vary from just a few to more than a hundred.

PN rarely occurs in circumscribed areas (typically in neuropathic pruritus). In general, PN lesions affect the extensor surfaces of the extremities and the trunk with a typical butterfly sign (that means the lack of lesions at the central back, which can be explained by the patient’s inability to scratch these skin areas). The face is rarely affected. For conducting clinical trials, it is important to have a reliable measurement tool to evaluate the disease activity. For PN, such a tool has not been made available till now. Therefore, it is a welcome sign that just recently a Prurigo Activity Score has been developed and validated 14. In addition, there are efforts to analyze prurigo activity by a computer-based software that would evaluate PN lesions automatically in an objective way 15.

For a deeper understanding of the different clinical features and pictures of PN during the time the patient is suffering from PN, a publication by Schedel et al. 16 should be referred. In that publication, it is clearly presented how dynamically the lesions behave during the course of the disease. After a nondefined time of chronic pruritus, PN lesions appear as a consequence of chronic-repetitive mechanical irritation (usually by scratching). This first appearance of PN is characterized by small papules that become bigger in size because of scratching and develop into nodules or even plaques. These stages of PN are therefore called papular type (Fig. 1), nodular type (Fig. 2), and plaque type prurigo (Fig. 3). In the course, these nodes can be massively excoriated, ulcerated (stage of ulcerated prurigo), or show crusts resulting in scars after healing. In some patients, no nodules but ulcerations with fibrosated edges of elevated and hyperplastic epidermis form resulting in the clinical picture of the umbilicated ulcerative prurigo. This was (in former times) described as an own entity (Kyrle’s disease).

Figure 1
Figure 1:
Papular type of prurigo.
Figure 2
Figure 2:
Nodular type of prurigo.
Figure 3
Figure 3:
Plaque type of prurigo.

Underlying diseases

Dermatological diseases

In up to 50% of PN patients there is an atopic predisposition, often also showing signs of atopic dermatitis 2. As PN is a specific clinical skin reaction pattern to chronic pruritus, PN can appear in many other dermatological diseases. Sometimes the clinical picture of PN can be so dominant that the originally underlying skin disease can get hidden by it. Examples for underlying dermatological diseases are scabies, stasis dermatitis, allergic contact dermatitis, lichen planus, bullous pemphigoid, dermatitis herpetiformis (Duhring), or even neoplastic diseases such as cutaneous lymphoma or multiple keratoacanthomata. Therefore, a histological examination involving routine histology of the lesion plus direct immunofluorescence of the surrounding skin of the lesion should be carried out to rule out the above-mentioned underlying diseases.

Systemic diseases

PN is an often described clinical picture of chronic renal failure. In a study with patients suffering from chronic renal failure, more than half of the patients showed PN lesions 17; in this trial, the duration of kidney disease correlated with the probability to suffer from PN.

Metabolic diseases such as diabetes mellitus can also lead to PN. The coexistence of chronic renal failure and diabetes mellitus even leads to a more active stage of PN, with umbilicated ulcerations; see Chapter ‘Clinical appearance of PN’ by Tseng et al.18.

Cholestatic diseases are known to lead to chronic pruritus and in some cases to the clinical picture of PN. However, in cholestatic pruritus, PN is an exception and patients suffer mostly from chronic pruritus on normally looking skin. Examples are primary sclerosing cholangitis, primary biliary cirrhosis, choledocholithiasis, or hepatocellular carcinoma 19.

Among viral hepatitides, hepatitis C is well-known to be often associated with chronic pruritus 20 and can sometimes also lead to PN 21. Other infectious diseases such as HIV are also well-known to frequently lead to the appearance of PN 22.

Neurological disease

Neurological diseases are sometimes the reason of localized PN. It is caused by irritation or damage of cutaneous and/or extracutaneous nerves. Examples are postherpetic neuralgia or brachioradial pruritus (often in dermatome C6) 23,24.

Psychiatric diseases

The clinical picture of PN can be erased by the so-called skin-picking disorder in which the patients scratch and maltreat their skin despite lack of pruritus 25. The result is the appearance of PN-like lesions. In addition, anxiety disorders, depressions, and tactile hallucinations can also lead to chronic pruritus and thereby to PN as well 26.

Treatment of prurigo nodularis

PN requires a multimodal itch therapy based on mainly two arms. The first one is the treatment of the potentially underlying disease, which can often lead to an improvement in the itch (e.g. successful treatment of underlying hepatitis C, HIV, renal and hepatic diseases). The second arm is the symptomatic antipruritic therapy, which is induced in parallel to the first arm and, if a causal therapy is not possible or if it does not lead to a sufficient therapeutic effect, should be maintained until all PN lesions are healed. For that, we have developed treatment algorithms for PN treatment (Fig. 4). The different treatment levels are explained in what follows.

Figure 4
Figure 4:
Algorithms of treatment of PN. PN, prurigo nodularis; SSRI, selective serotonin reuptake inhibitor.

Topical symptomatic treatments

Generally, clinical experience has shown that a basic topical therapy with moisturizing emollients exhibits antipruritic efficacy and is therefore always concomitantly recommended. Topical emollients are most often not completely sufficient, so that in daily practice the first-line topical treatment of PN is the use of topical steroids. However, there are just a few randomized clinical trials underlining its efficacy (e.g. betamethasone valerate 0.1% 27 or hydrocortisone 1% cream 28). On the bottom of the widespread use of topical calcineurin inhibitors (such as pimecrolimus cream and tacrolimus ointment) in atopic dermatitis, these substances are also sometimes used in PN cases not accordingly responding to topical steroids or because of the side effects of steroids. A randomized controlled trial showed that pimecrolimus 1% cream is as effective as hydrocortisone 1% cream in treating PN 28. In the case of only single PN lesion, an injection with triamcinolone acetonide is also possible 29. In localized neuropathic PN, such as brachioradial pruritus, the usage of topical capsaicin is an option. It can be either used as a cream in various concentrations (0.025–0.3%) for up to six times daily or as a ready to use patch 30,31.

Systemic symptomatic therapy

Antihistamines: Despite missing randomized trials for all kinds of systemic therapies and missing approval of systemic therapy for the treatment of PN, treatment with antihistamines is still the number one option of dermatologists for the systemic therapy of PN. Despite a convincing clinical effect of antihistamines, several patients benefit from a therapy with modern antihistamines. It is recommended to use high doses of nonsedative antihistamines (dosage of four times a day) if necessary, in addition to a sedative antihistamine at night 32. A combination with antileukotriene agents such as montelukast is also possible 33. A case series with 12 PN patients showed successful treatment with the antihistaminic fexofenadine 240 mg per day in combination with 10 mg of montelukast per day 33.

UV therapy: An alternative for further systemic treatment or addition to antihistamines and topical steroid or capsaicin treatment is the ultraviolet (UV) phototherapy. There are several case series and a single case report about successful treatment regimens with UVB, (bath) PUVA, UVB excimer laser therapy, or UVA 34–36.

However, the only randomized controlled trial is the one that compared bath PUVA with bath PUVA in combination with UVB 308 nm excimer light in 22 patients 37. The combination resulted in lower cumulative PUVA doses.

Generally, in daily practice UV therapy has many limitations as it is time-consuming and due to its potential carcinogenicity. Therefore, it is only appropriate for a specific target population.

Anticonvulsants: After failure of antihistamines and UV therapy, the group of anticonvulsants has been shown to be effective in PN treatment. Well-known from the therapy of chronic pruritus 38, there are several case reports in the field of treatment of PN 39,40. Our own clinical experience has shown that the antipruritic character of gabapentin seems to be superior to the one of pregabalin (clinical observation).

For the mode of action for both substances, it is postulated that they react as ligands of the α2–δ subunits of calcium channels of peripheral and central nociceptive neurons. Their binding results in calcium influx with the result of inhibition of depolarization of neuronal cells 41.

Antidepressants: Based on the results of the therapy of chronic pruritus, it is well-known that antidepressive agents have antipruritic properties. Both the group of the selective serotonin reuptake inhibitors (e.g. paroxetine and sertraline) 42–44 and the tetracyclic (e.g. mirtazapine) 45,46 and tricyclic antidepressants (e.g. amitryptiline, doxepin) 47,48 have been shown to be efficacious in treating chronic pruritus. In the case of PN as a subgroup of chronic pruritus, a two-arm, proof-of-concept study comparing the two selective serotonin reuptake inhibitors, paroxetine and fluvoxamine, in 50 PN patients resulted in complete healing of scratch lesions in 14 patients and partial remission in 17 49.

Opioid receptor antagonists: The μ opioid receptor antagonists naloxone (intravenous dosing) or naltrexone (oral administration) has been described to be efficacious in treating PN, with response rates of up to 67.5% 50. There are some randomized controlled trials reporting the effects on pruritus in different underlying diseases such as cholestatic pruritus 51,52. However, potential side effects such as dizziness, inability to drive, and nausea have been considered and discussed with the patients prior to the treatment initiation.

Immunosuppressive drugs: After failure or contraindication of the above-mentioned drugs, the use of immunosuppressive drugs such as cyclosporine A or methotrexate can be considered in adults. The dose of cyclosporine A is usually 3–5 mg/kg body weight and for methotrexate it is 7.5–20 mg once per week subcutaneously. A combination of cyclosporine A and methotrexate (each in a drastically reduced dosage) with the aim of reducing the side effects of cyclosporine A can be successful. In a case series of 14 patients treated with cyclosporine A, high response rates of greater than 90% have been detected 53. Strong results have also been reported in a retrospective observation of 13 patients treated with methotrexate 54. In addition to the case reports of the efficacious use of thalidomide in PN 55, recently two case reports about the use of its successor lenalidomide in treating PN have been reported 56,57.

Other immunosuppressive drugs such as oral tacrolimus have only been reported in single case reports, and thus the evidence of their efficacy is highly limited 58. The use of systemic steroids as pulse therapy can be considered as an initial therapy in patients with extremely high degree of suffering. However, long-term use is strictly contraindicated due to the known side effects of steroids after continued treatment duration.

Future therapies: During the last few years, treatment of PN has come under the focus of the medical community and the pharmaceutical industry, so that several clinical trials on the treatment of PN are currently in progress (DRKS00005594, NCT01963793, NCT02196324). Examples are ongoing trials on neurokinin-1 receptor antagonists aprepitant and serlopitant. As substance P as a major pruritogenic transmitter is the ligand of neurokinin-1 receptor, these receptor antagonists should have the potential to considerably reduce chronic pruritus in PN. Furthermore, a combination of µ-opioid receptor antagonist and κ-agonist nalbuphine is currently under observation in a clinical trial on treating PN (NCT02174419, NCT02174432).

With respect to the pruritic properties of IL-31 and its increase in PN lesion, a clinical trial of the recently developed IL-4/IL-13 and IL-31 antagonists might be promising as well.


The clinical pattern of PN should encourage the treating physicians to find potentially underlying diseases. Successful treatment of these diseases can lead to a rapid improvement in PN. If this approach fails or is not possible, a stepwise scheme has to developed to simplify and categorize a successful treatment of PN, both topically and systemically.


The authors thank Emily Burnett for the help in preparation of the manuscript.

The work was supported by the Federal Ministry of Education and Research (BMBF; no. 01KG1305)

Conflicts of interest

There are no conflicts of interest.


1. Tanaka M, Aiba S, Matsumura N, Aoyama H, Tagami H. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 1995; 190:269–276.
2. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2013; 27:550–557.
3. Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T, et al.. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol 2011; 38:310–320.
4. Thapa DP, Jha AK, Kharel C, Shrestha S. Ermatological problems in geriatric patients: a hospital based study. Nepal Med Coll J 2012; 14:193–195.
5. Amer A, Fischer H. Prurigo nodularis in a 9-year-old girl. Clin Pediatr (Phila) 2009; 48:93–95.
6. Eigelshoven S, Homey B. Prurigo nodularis. CME Dermatol 2009; 4:140–155.
7. Wyss-Chodat F. The treatment of pruriginous diseases with synthetic antihistamines. Ther Umsch 1962; 19:379–382.
8. Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002; 293:614–619.
9. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al.. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117:411–417.
10. Raap U, Wichmann K, Bruder M, Ständer S, Wedi B, Kapp A, Werfel T. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008; 122:421–423.
11. Liang Y, Marcusson JA, Jacobi HH, Haak-Frendscho M, Johansson O. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25:189–198.
12. Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusson JA, Johansson O. CGRP-immunoreactive nerves in prurigo nodularis – an exploration of neurogenic inflammation. J Cutan Pathol 2000; 27:359–366.
13. Schuhknecht B, Marziniak M, Wissel A, Phan NQ, Pappai D, Dangelmaier J, et al.. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol 2011; 165:85–91.
14. Schedel F, Charlotte Schürmann C, Matthias Augustin M, Metze D, Blome C, Zeidler C, Ständer S. Prurigo nodularis: introduction of a re-defined classification and Prurigo Activity Score (PAS) 17th World Congress on Itch (WCI) 2013. Acta Derm Verereol 2013; 93:599–640.
15. Bruland P, Hänse W, Schedel F, Ständer S, Fritz F. PIACS: a system for the automatic detection, categorization and comparison of scratch-related skin lesions in dermatology. Stud Health Technol Inform 2015; 216:1042.
16. Schedel F, Schürmann C, Metze D, Ständer S. Prurigo clinical definition and classification [article in German]. Hautarzt 2014; 65:684–690.
17. Böhme T, Heitkemper T, Mettang T, Phan NQ, Ständer S. Clinical features and prurigo nodularis in nephrogenic pruritus. Hautarzt 2014; 65:714–720.
18. Tseng HW, Ger LP, Liang CK, Liou HH, Lam HC. High prevalence of cutaneous manifestations in the elderly with diabetes mellitus: an institution-based cross-sectional study in Taiwan. J Eur Acad Dermatol Venereol 2015; 29:1631–1635.
19. Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015; 2015:295891.
20. Rahman A, Rizvi SD, Sheikh ZI. Frequency of HCV infection in different dermatological disorders. J Ayub Med Coll Abbottabad 2012; 24:58–61.
21. Mettang T, Vonend A, Raap U. Prurigo nodularis: its association with dermatoses and systemic disorders. Hautarzt 2014; 65:697–703.
22. Magand F, Nacher M, Cazorla C, Cambazard F, Marie DS, Couppié P. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg 2011; 105:401–404.
23. Mirzoyev SA, Davis MD. Brachioradial pruritus: Mayo Clinic experience over the past decade. Br J Dermatol 2013; 169:1007–1015.
24. Stumpf A, Ständer S. Neuropathic itch: diagnosis and management. Dermatol Ther 2013; 26:104–109.
25. Gieler U, Consoli SG, Tomás-Aragones L, Linder DM, Jemec GB, Poot F, et al.. Self-inflicted lesions in dermatology: terminology and classification – a position paper from the European Society for Dermatology and Psychiatry (ESDaP). Acta Derm Venereol 2013; 93:4–12.
26. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al.. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87:291–294.
27. Saraceno R, Chiricozzi A, Nisticò SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat 2010; 21:363–366.
28. Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, et al.. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology 2013; 227:353–360.
29. Richards RN. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg 2010; 14:19–23.
30. Zeidler C, Lüling H, Dieckhöfer A, Osada N, Schedel F, Steinke S, et al.. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol 2015; 172:1669–1671.
31. Goodless DR, Eaglstein WH. Brachioradial pruritus: treatment with topical capsaicin. J Am Acad Dermatol 1993; 29 (Pt 1):783–784.
32. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Ständer S. Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series. Hautarzt 2009; 60:564–568.
33. Shintani T, Ohata C, Koga H, Ohyama B, Hamada T, Nakama T, et al.. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther 2014; 27:135–139.
34. Hann SK, Cho MY, Park YK. UV treatment of generalized prurigo nodularis. Int J Dermatol 1990; 29:436–437.
35. Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691–695.
36. Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549–550.
37. Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308 nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799–803.
38. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19:3137–3139.
39. Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010; 23:194–198.
40. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther 2013; 38:16–18.
41. Baron A. AWMF guidelines for diagnostics and therapy in neurology: pharmacological, not interventional therapy of chronic neuropathic pain; 2012. Available at:
42. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000; 69:165–166.
43. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99:2627.
44. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16:121–124.
45. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25:288–291.
46. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50:889–891.
47. Smith KJ, Skelton HG, Yeager J, Lee RB, Wagner KF. Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997; 195:353–358.
48. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31:633–635.
49. Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, Schneider G. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89:45–51.
50. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680–688.
51. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, Candenas ML. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11:2045–2081.
52. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al.. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123:161–167.
53. Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008; 6:941–946.
54. Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol 2014; 39:468–473.
55. Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology 2011; 223:107–112.
56. Liu H, Gaspari AA, Schleichert R. Use of lenalidomide in treating refractory prurigo nodularis. J Drugs Dermatol 2013; 12:360–361.
57. Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol 2012; 148:794–796.
58. Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm Venereol 2015; 95:866–867.

antihistamines; aprepitant; chronic pruritus; prurigo activity score; prurigo nodularis

© 2016 Egyptian Women's Dermatologic Society